Thank you Dr. Deyrup for the excellent lecture, both in contents and presentation. I feel such a privilege to have discovered to access to your lectures, which further increased my interest in cancer pathology. I am a clinical pharmacist practising in oncology for the past 25 years. I have always been interested in pathology, initially because no retake exam was allowed for the basic medical pathology course during my postgraduate PharmD program, and then because pathology plays such an essential part of cancer care, that cancer pathology was mandatory for my MSc in Oncology program. For the past 15 years I have been trying to understand more in-depth because more and more new oncology drugs are targeting the molecular pathology of the tumours.
Thank you. Although aimed well above my knowledge level, your lesson is informative. I am a multiple myeloma patient whose risk classification changed recently due (in part) to p53 deletion. I now have an understanding how that genetic condition contributes to my resistance to chemotherapy. I am encouraged by the development of bispecific antibodies as a class of therapy.
I know the citations are included on your slides, but it would also be cool to have direct links to the papers you reference included in the video description, especially when you are talking about the future directions of TP53 mutant therapies
Thank you Dr. Deyrup for the excellent lecture, both in contents and presentation. I feel such a privilege to have discovered to access to your lectures, which further increased my interest in cancer pathology. I am a clinical pharmacist practising in oncology for the past 25 years. I have always been interested in pathology, initially because no retake exam was allowed for the basic medical pathology course during my postgraduate PharmD program, and then because pathology plays such an essential part of cancer care, that cancer pathology was mandatory for my MSc in Oncology program. For the past 15 years I have been trying to understand more in-depth because more and more new oncology drugs are targeting the molecular pathology of the tumours.
Great to meet you! Thank you for all your comments!
Thank you. Although aimed well above my knowledge level, your lesson is informative. I am a multiple myeloma patient whose risk classification changed recently due (in part) to p53 deletion. I now have an understanding how that genetic condition contributes to my resistance to chemotherapy. I am encouraged by the development of bispecific antibodies as a class of therapy.
I'm glad my video was able to help!
Amazing illustration, may you add presentation for signal transduction in lymphoid malignancies like NOTCH, MAPK, BRAF
Thank you Dr. ❤
Most welcome!
I know the citations are included on your slides, but it would also be cool to have direct links to the papers you reference included in the video description, especially when you are talking about the future directions of TP53 mutant therapies
That's an excellent suggestion! Working on it now!!
Can we mention that p53 gene is located at chromosome 17 p arm, so deletion of 17p is associated similar problems as p53 mutations
But p53 is not a drug target.
Amazing...loved how u summed it up ...
Thank you so much!!!